Search
Padimate O
go.drugbank.com/drugs/DB11570ApprovedPadimate O is an active sunscreen agent in cosmetics and over-the-counter sunscreen drug products in concentrations up to 8%, as regulated by the FDA [L2153]. … It penetrates human skin, and is shown to induce non-ligatable strand breaks on DNA _in vitro_ and mutagenic effects on yeast i_n vivo_ [A32458].
Mixtures: Skin Pro-tec II SPF-15, Dermatone SPF 23 Lips N Face ProtectorCategories: Compounds used in a research, industrial, or household settingGlipizide
go.drugbank.com/drugs/DB01067ApprovedInvestigationalAccording to the 2018 Clinical Practice Guidelines by Diabetes Canada, sulfonylurea drugs are considered a second-line glucose-lowering therapy following metformin. … It was first introduced in 1984 [A179491] and is available in various countries including Canada and the U.S.
Categories: Drugs Used in DiabetesSynonyms: N-{4-[β-(5-methylpyrazine-2-carboxamido)ethyl]benzenesulphonyl}-N'-cyclohexylureaSodium phosphate, dibasic
go.drugbank.com/drugs/DB14502ApprovedInvestigationalMixtures: Aminosyn II 7% M In 10% Dextrose(dual Chamber), Aminosyn II 8.5% M In 20% Dextrose (dual Chamber)Coagulation factor X human
go.drugbank.com/drugs/DB13148ApprovedInvestigationalHowever its use is limited in the perioperative setting for the management of bleeding in major surgery in patients with moderate and severe hereditary Factor X deficiency. … While Factor X normally circulates in the plasma as inactive molecules, the activation of Factor X is involved in both the intrinsic and extrinsic coagulation pathways.
Mixtures: COFACT 250 IU/10 ML IV ENJEKSIYON IÇIN TOZ IÇEREN FLAKON, 1 ADET, COFACT 500 IU/20 ML IV ENJEKSIYON IÇIN TOZ IÇEREN FLAKON, 1 ADETArtesunate
go.drugbank.com/drugs/DB09274ApprovedInvestigationalArtesunate is indicated for the initial treatment of severe malaria.[L14099] The World Health Organization recommends artesunate as first line treatment for severe malaria. … [A203948] Artesunate was granted FDA approval on 26 May 2020.[L14099]
Ribavirin
go.drugbank.com/drugs/DB00811ApprovedInvestigationalas an adjunct therapy to various first-line and second-line combination therapies recommended for each genotypes. … Combination therapy of ribavirin and [DB00008] results in the SVR of 44% in patients with genotype 1 infection and 70% in patients with genotype 2-6.
Mixtures: Rebetron Ready To Use Solution (albumin(human)free) (6000000 Iu/ml and 200mg Capsules)Degarelix
go.drugbank.com/drugs/DB06699ApprovedInvestigationalChemically, it is a synthetic linear decapeptide amide with seven unnatural amino acids, five of which are D-amino acids. FDA approved on December 24, 2008. … Reduction in testosterone is important in treating men with advanced prostate cancer.
Nafcillin
go.drugbank.com/drugs/DB00607ApprovedInvestigationalIt may be used as a first-line therapy in Methicillin-Sensitive *Staphylococcus aureus* infections [A20360]. … It is a beta-lactamase-resistant penicillin that is indicated for the treatment of Staphylococcal infections caused by strains that are resistant to other penicillins, except those caused by MRSA.
Elranatamab
go.drugbank.com/drugs/DB15395ApprovedInvestigationalIt is a humanized immunoglobulin 2-alanine kappa antibody derived from two monoclonal antibodies (mAbs), an anti-BCMA mAb and an anti-CD3 mAb,[A261060] each of which contributes one heavy chain and one … Elranatamab is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager.
Tisagenlecleucel
go.drugbank.com/drugs/DB13881ApprovedInvestigationalIt was granted approval by FDA in August 2017 under the market name Kymriah. … In a multicenter clinical trial involving pediatric and young adult patients with relapsed or refractory B-cell precursor ALL, the overall remission rate within three months of treatment was 83 percent